Functional MRI and CT biomarkers in oncology

被引:0
作者
J. M. Winfield
G. S. Payne
N. M. deSouza
机构
[1] Institute of Cancer Research and Royal Marsden NHS Foundation Trust,CRUK Imaging Centre at the Institute of Cancer Research
[2] Institute of Cancer Research and Royal Marsden Hospital,MRI Unit
来源
European Journal of Nuclear Medicine and Molecular Imaging | 2015年 / 42卷
关键词
MRI; CT; Biomarker; Oncology;
D O I
暂无
中图分类号
学科分类号
摘要
Imaging biomarkers derived from MRI or CT describe functional properties of tumours and normal tissues. They are finding increasing numbers of applications in diagnosis, monitoring of response to treatment and assessment of progression or recurrence. Imaging biomarkers also provide scope for assessment of heterogeneity within and between lesions. A wide variety of functional parameters have been investigated for use as biomarkers in oncology. Some imaging techniques are used routinely in clinical applications while others are currently restricted to clinical trials or preclinical studies. Apparent diffusion coefficient, magnetization transfer ratio and native T1 relaxation time provide information about structure and organization of tissues. Vascular properties may be described using parameters derived from dynamic contrast-enhanced MRI, dynamic contrast-enhanced CT, transverse relaxation rate (R2*), vessel size index and relative blood volume, while magnetic resonance spectroscopy may be used to probe the metabolic profile of tumours. This review describes the mechanisms of contrast underpinning each technique and the technical requirements for robust and reproducible imaging. The current status of each biomarker is described in terms of its validation, qualification and clinical applications, followed by a discussion of the current limitations and future perspectives.
引用
收藏
页码:562 / 578
页数:16
相关论文
共 682 条
[1]  
Charles-Edwards EM(2006)Diffusion-weighted magnetic resonance imaging and its application to cancer Cancer Imaging 6 135-143
[2]  
de Souza NM(2008)Technology insight: water diffusion MRI – a potential new biomarker of response to cancer therapy Nat Clin Pract Oncol 5 220-233
[3]  
Patterson DM(1991)Imaging of diffusion and microcirculation with gradient sensitization: design, strategy and significance J Magn Reson Imaging 1 7-28
[4]  
Padhani AR(2012)Apparent diffusion coefficient from magnetic resonance imaging as a biomarker in oncology drug development Eur J Cancer 48 425-431
[5]  
Collins DJ(2012)Tumour response prediction by diffusion-weighted MR imaging: ready for clinical use? Crit Rev Oncol Hematol 83 194-207
[6]  
LeBihan D(2009)Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations Neoplasia 11 102-125
[7]  
Turner R(2013)Diffusion-weighted MR imaging in liver metastases of colorectal cancer: reproducibility and biological validation Eur Radiol 23 748-756
[8]  
Moonen CT(2011)Metastatic ovarian and primary peritoneal cancer: assessing chemotherapy response with diffusion-weighted MR imaging – value of histogram analysis of apparent diffusion coefficients Radiology 261 182-192
[9]  
Pekar J(2009)Reproducibility and changes in the apparent diffusion coefficient of solid tumours treated with combretastatin A4 phosphate and bevacizumab in a two-centre phase I clinical trial Eur Radiol 19 2728-2738
[10]  
Sinkus R(2014)Diffusion-weighted MR imaging of upper abdominal organs: field strength and intervendor variability of apparent diffusion coefficients Radiology 270 454-463